This article is more than 5 years old. Information may no longer be current.
Two researchers chosen for ASH faculty development program
Click Here to Manage Email Alerts
Justin Taylor, MD, of Memorial Sloan Kettering Cancer Center and Roger Belizaire, MD, PhD, of Brigham and Women’s Hospital have been chosen to participate in the ASH–Harold Amos Medical Faculty Development Program.
The program — designed to increase the number of underrepresented minority scholars in the field of hematology with academic and research appointments — provides 4-year research awards that include an annual stipend of up to $75,000 and an annual research grant of $30,000.
Taylor and Belizaire will spend at least 70% of their funded research under the mentorship of senior faculty at their institutions.
Taylor will investigate the underlying mechanisms and consequences of alterations to XPO1, a protein thought to drive several types of blood cancers and other malignancies. Belizaire’s research will focus on CBL, a cell signaling protein that is mutated in myeloid malignancies and drives cell proliferation and myeloid differentiation.
“I’m proud that ASH will support Drs. Taylor and Belizaire in their work, which may lead to novel, more effective, and well-tolerated targeted therapies,” ASH President Kenneth C. Anderson, MD, of Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute, said in a press release. “The [ASH–Harold Amos Medical Faculty Development Program] is strengthening the hematology workforce by attracting underrepresented minorities to the field and providing support and stability so recipients can focus on the work that will enhance their careers in hematology.”